Positron Moves into New PosiRx Manufacturing Facility

INDIANAPOLIS--(BUSINESS WIRE)-- Positron Corporation (OTCBB:POSC) (“Positron”, or the “Company”), Positron Corporation a leading molecular imaging company specializing in the field of nuclear cardiology, announces the relocation of their PosiRx manufacturing, product research and development facility. The new office is approximately three miles from our current Fishers, IN location.

The facility, approximately 10,000 sq. ft., provides ample space for Positron’s engineering development, equipment manufacturing, and research departments. The new facility enables Positron to consolidate two existing central Indiana sites at one campus: improving communication, reducing expenditures and increasing productivity. The new location, 9715 Kincaid Blvd. will also serve as an interim headquarters facility for Positron's future cyclotron project in the neighboring city of Noblesville. This move will not impact Positron’s current radiopharmaceutical manufacturing facility in Crown Point, Indiana.

The new location will also serve as a PosiRx product showcase and training facility for our clients and potential customers. "I am excited to be able to move our people and products into a single facility that is both close to our previous locations and to our future home in Noblesville,” states Scott Stiffler, VP of Pharmaceuticals. “Our new location, with its enhanced operational efficiencies and production capabilities, allows us to meet the demand for PosiRx and will accelerate our new product development projects.”

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron Corporation provides innovative molecular technologies and services that are reshaping the field of nuclear cardiology through proprietary PET imaging and radiopharmaceutical solutions with a strong commitment to advancing the practice and technology of nuclear medicine. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.



CONTACT:

Positron Corporation
Patrick Rooney, 866.613.7587
Chief Executive Officer

KEYWORDS:   United States  North America  Indiana

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Hospitals  Medical Devices  Pharmaceutical  Radiology  General Health

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.